

Test Report: EN 14476 2005 Chemical disinfectants and antiseptics - Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine - Test method and requirements (phase 2/step 1) Modification for surface testing and Respiratory Syncytial Virus a surrogate for Ebola virus.

Test Laboratory

BluTest Laboratories Ltd

Robertson Incubator (Level 4)
Robertson Building
56 Dumbarton Road
Glasgow
UK - G11 6NU

Identification of sample

Name of the product
Batch number
Client

Serenity Alcohol Free Hand sanitiser

Not specified
Serenity Group
Kemp House, London, EC1V 2NX
BT-CNL-01
22 Oct 2014
Tightly sealed, original container. Well ventilated, cool place
Not specified

Project Code
Date of Delivery
Storage conditions

Active substances

Test Method and its validation

Method

1 part interfering substance + 1 part virus suspension + 8 parts biocide were mixed and incubated at the indicated contact temperature for the indicated contact times. Assays were validated by a cytotoxicity control, interference control, neutralization control and a formaldehyde internal standard.

Neutralization

Dilution-neutralization/gel filtration; Dulbecco's modified Eagles medium + 5% v/v foetal bovine serum at 4°C

Experimental Conditions

Period of analysis
Product diluents used
Product test concentrations
Appearance product dilutions
Contact times (minutes)
Test temperature
Interfering substances
Stability of mixture
Temperature of incubation
Identification of virus

31-Oct-14 to 25-Nov-14
Sterile distilled water
1.0%V/V; 50.0% V/V; 80.0% V/V
Clear
1 ± 10s;
20°C ± 1°C
0.3g/l bovine albumin
Stable under normal conditions
37°C ± 1°C + 5% CO₂
Respiratory Syncytial virus/Hep2 cells

PROTOCOL SUMMARY

The basic virucidal efficacy test is set up with one test per three concentrations of disinfectant and a 1 minute contact time. Virus is exposed to disinfectant in 24-well plates, then neutralized, serially diluted and virus titred in 96-well tissue culture plates to determine the tissue culture infectious dose₅₀ (TCID₅₀) of surviving virus. TCID₅₀ is determined by the method of Karber¹.

Cytotoxicity control

The neutralized disinfectant is measured for its effects on the host cells used to propagate the virus, to determine the sensitivity of the assay.

Interference control

The end point titration of the virus is exposed to three different sub-lethal concentrations of neutralized disinfectant to measure the effect of sub-lethal concentrations of disinfectant on virus infectivity in relation to the titre achieved on untreated cells.

Disinfectant suppression control

Virus is added to the highest concentration of disinfectant and then the mixture removed and neutralized. The neutralized virus titre is then determined to assess the efficiency of the neutralization procedure.

Virus recovery control

Virus titre is determined for virus in contact with sterile hard water at t=0, t=1 and at t = 60. The virus titre after 1 minute is then compared to the recovery of disinfectant-treated virus to measure the log reduction in virus titre. The virus titre after 60 minutes is compared to the reference virus inactivation control.

Reference virus inactivation control

Virus is in contact with 0.7% W/V formaldehyde and the recovery of virus determined by TCID₅₀ after 5, 15, 30 and 60 minutes, in order to assess that the test virus has retained reproducible biocide resistance. In addition, the formaldehyde cytotoxicity of neutralized formaldehyde is determined, to measure assay sensitivity.

¹Kärber, G.: Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche. Arch. Exp. Path. Pharmak. 162 (1931): 480-487.

Surface test results for the efficacy of Serenity Alcohol Free Hand Sanitiser from Serenity Group Ltd against Respiratory Syncytial virus under CLEAN CONDITIONS

Exposure Time	Virus Recovery 0 min		Virus Recovery 1 min		Cytotoxicity		Disinfectant Suppression		1.0% (v/v)		50.0% (v/v)		80.0% (v/v)	
	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml
t = 1 min	5.33	6.76E+06	5.33	6.76E+06	1.00	3.16E+02	2.00	3.16E+03	2.50	1.00E+04	1.50	1.00E+03	2.00	3.16E+03
log difference		6.83		6.83		2.50		3.50		4.00		3.00		3.50
								3.33		2.83		3.83		3.33

Table of results of virucidal activity against RSV under clean conditions for Serenity Alcohol Free Hand Sanitiser from Serenity Group Ltd

Product:	Interfering substance	Concentration	Level of cytotoxicity	1g TCID50						
				0 min	1 m (prod)/ 5 m (form)	15 min	30min	60 min	>4 lg reduction after .. Min	
Alcohol Free Hand sanitiser	0.3g/l BSA	80.0% (v/v)	2.50	6.83	3.50	na	na	na	na	>1
		50.0% (v/v)	2.50	6.83	3.00	na	na	na	na	>1
		1.0% (v/v)	2.50	6.83	4.00	na	na	na	na	>1
Formaldehyde		0.07% (w/v)	1.50	6.83	5.17	4.17	3.17	2.00	2.00	30
Virus Control		n.a.	n.a.	6.83	6.83	n.a.	n.a.	7.17	n.a.	n.a.

Control Data

Control Data for: BT-CNL-01 RSV

Stock Virus (TCID ₅₀)	7.33	6.76E+08
-----------------------------------	------	----------

Formaldehyde reference inactivation control

Exposure time	Virus recovery 0 min		Virus recovery 60 min		Cytotoxicity		0.07% Formaldehyde							
	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	raw data	TCID ₅₀ /ml	5		15		30		60	
60 min	5.33	6.76E+06	5.67	1.48E+07	0.00	3.16E+01	3.67	1.48E+05	2.67	1.48E+04	1.67	1.48E+03	0.50	1.00E+02
log difference	6.76E+06	6.83	1.48E+07	7.17	3.16E+01	1.50	5.17	2.00	4.17	3.00	3.17	4.00	2.00	5.17

No Column Control

Virus Recovery 30 min	
raw data	TCID ₅₀ /ml
5.50	1.00E+07
	1.00E+07
	7.00

Interference control

Virus dilution	Cytotoxicity dilution					
	-1	-2	-3	Mock		
-5	C	C	3	3		
-6	C	C	1	2		
-7	C	C	0	1		

CONCLUSION

Verification of the methodology

A test is only valid if the following criteria are fulfilled:

- a) Test virus suspension has at least a concentration which allows the determination of a 4 log₁₀ reduction of the virus titre.
- b) Detectable titre reduction is at least 4 log₁₀.
- c) Difference of the logarithmic titre of the virus control minus the logarithmic titre of the test virus in the reference inactivation test is between – 0.5 and – 2.5 after 30 min and between – 2 and – 4.5 after 60 min for poliovirus.
- d) Cytotoxicity of the product solution does not affect cell morphology and growth or susceptibility for the test virus in the dilutions of the test mixtures which are necessary to demonstrate a 4 log reduction of the virus.
- e) The interference control result does not show a difference of < 1.0 log₁₀ of virus titre in comparison to the virus recovery control; dilutions of disinfectant to sub-acute levels did not interfere in the generation of viral cytopathic effect.
- e) Neutralisation validation. This is called the disinfectant suppression test in this protocol. The difference for virus is slightly elevated probably indicating rapid irreversible virucidal activity of the disinfectant by dilution at a concentration of 80.0% v/v.
- f) A difference of <0.5 log₁₀ is not observed between virus recovered directly from the virus recovery control at 60 minutes and virus from the same control recovered through an Illustra Microspin S-400 HR column

According to EN 14476 2005, **Serenity Alcohol Free Hand sanitiser POSSESSES VIRUCIDAL** activity at a concentration of **50.0 % V/V** of the working concentration as tested after **1 MINUTE** at **20°C** under **CLEAN** conditions (0.3 g/l bovine albumin) of **>3.83 log₁₀** against **Respiratory Syncytial virus, a surrogate for Ebola virus.**

The result at 80.0% V/V of the working concentration was not demonstrated because residual cytotoxicity of the product reduced the sensitivity of the assay.

Signed



Dr Chris Woodall, Director
BluTest Laboratories Ltd
Glasgow, UK
Date: 10 December 2014

Ebola virus

Order: Mononegvirales
Family: Filoviridae
Genus: Ebolavirus
Species: Ebola virus

Respiratory syncytial virus

Mononegvirales
Paramyxoviridae
Pneumovirus
Human respiratory syncytial virus

Source: International Committee on the Taxonomy of Viruses (2013 update).

A virus is a member of the order Mononegvirales if:

its genome is a linear, non-segmented, single-stranded, non-infectious RNA of negative polarity; possesses inverse-complementary 3' and 5' termini; is not covalently linked to a protein

its genome has the characteristic gene order 3'-UTR-core protein genes-envelope protein genes-RNA-dependent RNA polymerase gene-5'-UTR

it produces 5–10 distinct mRNAs from its genome via polar sequential transcription from a single promoter located at the 3' end of the genome; mRNAs are 5' capped and polyadenylated

it replicates by synthesizing complete antigenomes

it forms infectious helical ribonucleocapsids as the templates for the synthesis of mRNAs, antigenomes, and genomes


it encodes an RNA-dependent RNA polymerase (RdRp) that is highly homologous to those of other mononegaviruses

it forms enveloped virions with a molecular mass of $300-1,000 \times 10^6$; an S20W of $550 \rightarrow 1,045$; and a buoyant density in CsCl of $1.18-1.22 \text{ g/cm}^3$

Easton, C. R.; Pringle (2011), "Order Mononegvirales", in King, Andrew M. Q.; Adams, Michael J.; Carstens, Eric B. et al., Virus Taxonomy—Ninth Report of the International Committee on Taxonomy of Viruses, London, UK: Elsevier/Academic Press, pp. 653–657, ISBN 978-0-12-384684-6



Ebola virus



RSV

DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with a modified 14476 surface protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with: (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.